Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in Female Participants With Stress Urinary Incontinence and Obesity or Overweight
NCT07202884Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of orforglipron in stress urinary incontinence (SUI), obesity, sponsored by Eli Lilly and Company. Started Sep 2025; status: recruiting.
02
Drugs
orforglipron
03
Conditions
stress urinary incontinence (SUI)obesity
Beyond the preview
Go deeper on NCT07202884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07202884.